In order to further promote the management of chronic psoriasis and standardize diagnosis and treatment, it is sponsored by the Psoriasis Professional Committee of the Chinese Medical Association Dermatovenereology Branch and the Anhui Health Service Association The 22nd issue of "2020 China Psoriasis Diagnosis and Treatment Guidelines Tour, Dandelion Action and GPA Online Training Conference" was successfully held on December 12, 2020 on the Umaid online platform.

        This meeting was co-chaired by Professor Li Shanshan, Director of Dermatology Department of Jilin University First Hospital, and Professor Zhang Chunlei, Director of Dermatology Department of Peking University Third Hospital. Professor Chen Yongfeng, Vice President of the Dermatology Hospital of Southern Medical University, Director of the Department of Preventive Medicine of Guangdong Province, Professor Liu Quanzhong, Doctoral Supervisor of Tianjin University General Hospital of Medical Sciences, Standing Committee Member of the Chinese Medical Association Dermatology Branch, and Vice Chairman of the 12th Session, Jilin Professor Liu Hesong, deputy director of the Dermatology Department of University First Hospital, chairman of the Dermatology Committee of Jilin Provincial Health Management Society, Professor Zhou Junfeng, deputy director of the Department of Dermatology of Jilin University First Hospital, Professor Guan Xin, deputy director of Peking University Third Hospital, colleagues in the national dermatology department More than 500 people, including patients with psoriasis, and business representatives, participated in this online conference.

        Professor Zhang Chunlei started the conference and introduced the background and significance of the whole project in detail. Next, Dr. Guan Xin shared the "Introduction to China's GPA Project, Task Arrangement and Survey Form Filling Training". GPA is a global psoriasis surveillance project. With the strong support of the international GPA project, the Chinese Psoriasis Surveillance Project (CGPA) was established under the leadership of the Psoriasis Professional Committee (CPC) of the Dermatology Branch of the Chinese Medical Association. To understand the current prevalence of psoriasis in China, to establish a long-term follow-up cohort of psoriasis in China to provide information on the research, policy and health care of the disease in China. At this stage, relying on the GPA China Surveillance Point and the Psoriasis Specialty Clinic, recruit psoriasis patients across the country to participate in the psoriasis questionnaire survey, and complete the epidemiological survey of GPA psoriasis patients. Then, Dr. Guan Xin introduced the CGPA electronic system training in detail, and briefly reviewed the outstanding work done by the Psoriasis Committee in 2020.

        Professor Chen Yongfeng shared a guide to the protracted battle of psoriasis treatment. Mainly from the overview of psoriasis, the long-term harm caused by psoriasis, and the need for long-term and durable management of psoriasis. Psoriasis is a chronic, recurrent, inflammatory, and systemic disease with a high incidence, which seriously affects the quality of life of patients. Psoriasis patients usually have comorbidities such as cardiovascular disease, metabolic syndrome, and mental-related diseases. The burden of the disease is heavy. Psoriasis needs long-term control of the disease. Interruption of treatment will inevitably cause disease recurrence. Psoriasis recurrence is mostly in situ recurrence. It is highly correlated with the number of TRM cells and genetic changes. IL-23 inhibitors can deeply alleviate inflammation, control skin lesions for a long time, continuously improve the quality of life of patients, and have a good positive effect on patients' mental health.

        Professor Liu Quanzhong combined his own clinical experience to give a detailed interpretation of the latest edition of the "Chinese Expert Consensus on Psoriasis Biotherapy". The main content includes the patient population to which biological agents are adapted, the use of various biological agents, the evaluation of efficacy, as well as the curative effect reduction strategies of biological treatments and the application of biological agents to special populations. In particular, it focuses on the interpretation of the screening before the use of biological therapy and the monitoring during the treatment process, emphasizing that psoriasis requires long-term treatment. While controlling the symptoms of psoriasis, it is also necessary to pay attention to the infection caused by biological agents. risks of.

        Professor Zhou Junfeng shared "Walk into 2020EADV, and see the latest research progress in psoriasis biotherapy", bringing you the international psoriasis treatment Frontier progress. Professor Zhou focused on sharing the two latest international head-to-head studies of biologics, the IXORA study and the ECLIPSE study, which provided evidence-based evidence for guiding clinicians on how to choose biologics: IL-17 inhibitors seem to have a short-term effect. , But the long-term efficacy of IL-23 inhibitors is more durable and stable. Because IL-17 inhibitors inhibit normal immunity, the maintenance treatment of severe skin diseases is not as good as IL-23 inhibitors.

        Professor Liu Hesong finally shared "Find the key points of psoriasis accurately and get out of the "silver" shadow". Emphasize that cytokines are the key to the inflammatory response of psoriasis, including TNFα, IL-12, IL-23, and IL-17, among which IL-23 plays a "regulatory role" in the most critical response pathway and is an important core cytokine . Biological agents targeting cytokines have better curative effects than traditional system therapy drugs, constantly refreshing the clearance rate of psoriasis, effectively improving the quality of life of patients, the rate of sustained use and satisfaction of patients is high, and treatment standards have been formed, thus Ensure the safety of patients. Finally, it is pointed out that the long-lasting efficacy of biological agents is very suitable for long-term management of psoriasis.

In the following discussion topics, the professors spoke freely and pointed out their own experience in the treatment of psoriasis, how to manage patients for a long time, and what should be paid attention to in the screening of psoriasis biologics before medication. A heated discussion.

Finally, Professor Li Shanshan summarized the meeting. I believe that there are abundant treatment methods in the clinic, coupled with the implementation of the national medical insurance policy, more and more patients will benefit, which can make the treatment of psoriasis patients more effective. Standardization allows more psoriasis patients to receive individualized and optimized treatment.